MA50996A - Traitement du vrs avec une association médicamenteuse - Google Patents
Traitement du vrs avec une association médicamenteuseInfo
- Publication number
- MA50996A MA50996A MA050996A MA50996A MA50996A MA 50996 A MA50996 A MA 50996A MA 050996 A MA050996 A MA 050996A MA 50996 A MA50996 A MA 50996A MA 50996 A MA50996 A MA 50996A
- Authority
- MA
- Morocco
- Prior art keywords
- rsv
- treatment
- medication combination
- medication
- combination
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17205428 | 2017-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50996A true MA50996A (fr) | 2020-10-14 |
Family
ID=60582448
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050996A MA50996A (fr) | 2017-12-05 | 2018-12-04 | Traitement du vrs avec une association médicamenteuse |
| MA050995A MA50995A (fr) | 2017-12-05 | 2018-12-04 | Traitement du vrs avec une association médicamenteuse |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050995A MA50995A (fr) | 2017-12-05 | 2018-12-04 | Traitement du vrs avec une association médicamenteuse |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11369612B2 (fr) |
| EP (1) | EP3720440B1 (fr) |
| JP (1) | JP7293225B2 (fr) |
| KR (1) | KR20200096488A (fr) |
| CN (1) | CN111491633A (fr) |
| AU (1) | AU2018379230A1 (fr) |
| BR (1) | BR112020010878A2 (fr) |
| CA (1) | CA3079637A1 (fr) |
| CL (1) | CL2020001429A1 (fr) |
| EA (1) | EA202091363A1 (fr) |
| IL (1) | IL275027A (fr) |
| MA (2) | MA50996A (fr) |
| MX (1) | MX2020005847A (fr) |
| PH (1) | PH12020550869A1 (fr) |
| SG (1) | SG11202004987WA (fr) |
| TW (1) | TW201936193A (fr) |
| WO (1) | WO2019110563A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023528969A (ja) * | 2020-06-11 | 2023-07-06 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | ３－（｛５－クロロ－１－［３－（メチルスルホニル）プロピル］－１Ｈ－インドール－２ イル｝メチル）－１－（２，２，２－トリフルオロエチル）－１，３－ジヒドロ－２Ｈ－イミダゾ［４，５－ｃ］ピリジン－２－オンのヘミ（Ｌ）－酒石酸塩形態及びそれを含む医薬組成物 |
| CN116528850B (zh) | 2020-10-28 | 2025-08-22 | 盐野义制药株式会社 | 具有抗病毒活性的酰胺衍生物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6245789B1 (en) * | 1998-05-19 | 2001-06-12 | The Procter & Gamble Company | HIV and viral treatment |
| TWI515187B (zh) | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之吲哚類 |
| CA2931073C (fr) * | 2013-12-23 | 2021-10-26 | Novartis Ag | Combinaisons pharmaceutiques |
| JO3637B1 (ar) * | 2015-04-28 | 2020-08-27 | Janssen Sciences Ireland Uc | مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv |
| BR112018014958A2 (pt) | 2016-02-03 | 2019-01-08 | Janssen Sciences Ireland Uc | produtos de combinação para o tratamento de rsv |
-
2018
- 2018-12-03 TW TW107143199A patent/TW201936193A/zh unknown
- 2018-12-04 SG SG11202004987WA patent/SG11202004987WA/en unknown
- 2018-12-04 JP JP2020530351A patent/JP7293225B2/ja active Active
- 2018-12-04 CA CA3079637A patent/CA3079637A1/fr active Pending
- 2018-12-04 AU AU2018379230A patent/AU2018379230A1/en not_active Abandoned
- 2018-12-04 EA EA202091363A patent/EA202091363A1/ru unknown
- 2018-12-04 US US16/770,014 patent/US11369612B2/en active Active
- 2018-12-04 MA MA050996A patent/MA50996A/fr unknown
- 2018-12-04 BR BR112020010878-2A patent/BR112020010878A2/pt not_active IP Right Cessation
- 2018-12-04 MX MX2020005847A patent/MX2020005847A/es unknown
- 2018-12-04 CN CN201880078571.3A patent/CN111491633A/zh active Pending
- 2018-12-04 MA MA050995A patent/MA50995A/fr unknown
- 2018-12-04 KR KR1020207012272A patent/KR20200096488A/ko not_active Ceased
- 2018-12-04 WO PCT/EP2018/083440 patent/WO2019110563A1/fr not_active Ceased
- 2018-12-04 EP EP18811555.4A patent/EP3720440B1/fr active Active
-
2020
- 2020-05-28 CL CL2020001429A patent/CL2020001429A1/es unknown
- 2020-06-01 IL IL275027A patent/IL275027A/en unknown
- 2020-06-11 PH PH12020550869A patent/PH12020550869A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7293225B2 (ja) | 2023-06-19 |
| MX2020005847A (es) | 2020-09-07 |
| IL275027A (en) | 2020-07-30 |
| US20210236496A1 (en) | 2021-08-05 |
| WO2019110563A1 (fr) | 2019-06-13 |
| EP3720440A1 (fr) | 2020-10-14 |
| PH12020550869A1 (en) | 2021-05-17 |
| SG11202004987WA (en) | 2020-06-29 |
| EP3720440B1 (fr) | 2023-05-24 |
| US11369612B2 (en) | 2022-06-28 |
| AU2018379230A1 (en) | 2020-04-23 |
| TW201936193A (zh) | 2019-09-16 |
| EA202091363A1 (ru) | 2020-09-03 |
| BR112020010878A2 (pt) | 2020-11-10 |
| MA50995A (fr) | 2020-10-14 |
| KR20200096488A (ko) | 2020-08-12 |
| CL2020001429A1 (es) | 2020-09-25 |
| CN111491633A (zh) | 2020-08-04 |
| CA3079637A1 (fr) | 2019-06-13 |
| JP2021505559A (ja) | 2021-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL254769B (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| MA45192A (fr) | Traitement d'association | |
| IL264626A (en) | Composition for prophylaxis or treatment of il-8 related diseases | |
| EP3432888A4 (fr) | Traitement du cancer avec tg02 | |
| DK3328880T3 (da) | Terapeutiske midler | |
| EP3399972A4 (fr) | Traitement thérapeutique à faible dose | |
| EP3448263A4 (fr) | Traitement électrothérapeutique | |
| MA40764A (fr) | Agent thérapeutique induisant une cytotoxicité | |
| HUE065652T2 (hu) | Imidazo-pirazinon vázzal rendelkezõ PED9 inhibitor perifériális betegségek kezelésére | |
| EP3362065A4 (fr) | Polythérapie pour le traitement de malignités | |
| HUE045234T2 (hu) | Gyógyszeradagolás tanulása | |
| MA47408A (fr) | Traitement du cancer | |
| HUE047542T2 (hu) | A rák kombinált kezelése | |
| EP3468594A4 (fr) | Thérapie génique de céroïdes-lipofuscinoses neuronales | |
| EP3352586A4 (fr) | Traitement nutritionnel anticancéreux | |
| EP3424940A4 (fr) | Médicament radiomarqué | |
| EP3375108A4 (fr) | Traitement dewlan | |
| HUE060517T2 (hu) | Immunhiányos betegség kezelésére szolgáló eljárások | |
| EP3347334A4 (fr) | Déshydrohalogénation d'hydrochlorofluorocarbones | |
| DK3408265T3 (da) | Terapeutiske forbindelser | |
| HUE061656T2 (hu) | Metabolikus betegségek kezelése a miosztatin aktiválás gátlásával | |
| EP3630331C0 (fr) | Traitement de fluide | |
| IL262851A (en) | Combination prime: boost therapy | |
| EP3733175A4 (fr) | Traitement du cancer | |
| LT3600315T (lt) | Naujas terapinis h3 ligandų panaudojimas |